DOS47 Drug Candidates
Our most advanced Tumor Defence Breaker L-DOS47 is currently in clinical trials for the treatment of small cell lung cancer (NSCLC) and pancreatic cancer. A second DOS47 candidate, known as V-DOS47, targets the vascular epithelial growth factor receptor 2 and is at preclinical development.
L-DOS47 monotherapy NSCLC (clinical trial # NCT02340208)
L-DOS47 VIN/CIS combo NSCLC (clinical trial # NCT03891173)
L-DOS47 combo PEM/CARBO NSCLC (clinical trial # NCT02309892)
L-DOS47 DOXO combo Pancreas (clinical trial # NCT04203641)
L-DOS47 combo Immune Checkpoints